Recursion Pharmaceuticals (RXRX) has been drawing attention after recent trading, with the stock closing at $4.67. Investors are weighing this price against the company’s clinical pipeline and ongoing ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

According to @godofprompt, recursive prompting is an AI technique where system outputs are fed back in as inputs to refine solutions through multiple iterations (source: @godofprompt, Dec 16, 2025).

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.41187 EPS, ...

Abstract: This article introduces an event-triggered multigradient recursive data-driven iterative learning control (ETMGR-DDILC) scheme designed for consensus tracking in multiagent systems (MASs).

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...